1. Risk of Statin-Induced Hypertransaminasemia
Rosanna Villani, MD, PhD, Eliano Pio Navarese, MD, PhD, Francesco Cavallone, MD, Jacek Kubica, MD, PhD, Francesco Bellanti, MD, PhD, Antonio Facciorusso, MD, Gianluigi Vendemiale, MD, Gaetano Serviddio, MD 
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  
Volume 3, Issue 2, Pages (June 2019)
DOI: /j.mayocpiqo
Copyright © 2019 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Flow diagram of the review process according to the Preferred Reporting Items for Systematic reviews and meta-analysis (PRISMA) statement.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2019 3, DOI: ( /j.mayocpiqo )
Copyright © 2019 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
Analysis of odds ratios and 95% confidence intervals for overall risk of hypertransaminasemia.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2019 3, DOI: ( /j.mayocpiqo )
Copyright © 2019 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Figure 3
Analysis of odds ratios and 95% confidence intervals for hypertransaminasemia during high-dose statin therapy.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2019 3, DOI: ( /j.mayocpiqo )
Copyright © 2019 Mayo Foundation for Medical Education and Research Terms and Conditions

5. Figure 4
Analysis of odds ratios and 95% confidence intervals for hypertransaminasemia during low-dose statin therapy.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2019 3, DOI: ( /j.mayocpiqo )
Copyright © 2019 Mayo Foundation for Medical Education and Research Terms and Conditions